PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 4, 2026Trials1 citationsOpen Access

Efficacy of a plant-based diet on FOLFOX chemotherapy-induced gastrointestinal toxicity in patients with colorectal cancer: study protocol for a multicentre, stratified, randomised controlled trial

WPWei PengHSHongrui ShiLFLiang Fan

Key Points

  • To evaluate if a structured plant-based diet can reduce gastrointestinal toxicity during FOLFOX chemotherapy and improve related outcomes in colorectal cancer patients.
  • Multicentre, stratified, randomised controlled trial design
  • Enrolment of 114 adults aged 18-65 with confirmed colorectal cancer
  • Randomisation into three groups: plant-based diet, conventional dietary guidance, or guidance plus nutritional formula for 6 weeks
  • Assessments at baseline and at prescribed time points during the trial
  • Primary outcomes include incidence of gastrointestinal toxicity, inflammatory biomarkers, and stool profiling.
  • Expected reduction in the incidence of grade ≥ 2 gastrointestinal toxicity
  • Improvements in serum biomarkers related to inflammation
  • Potential positive changes in stool profiling for gastrointestinal health
  • Secondary outcomes will include enhancements in dietary intake, body composition, and mental health indicators.

Abstract

Abstract Background Gastrointestinal toxicity during FOLFOX chemotherapy for colorectal cancer (CRC) is frequent and can impair oral intake, quality of life, and planned chemotherapy delivery. Safe and scalable dietary strategies are needed as adjuncts to standard supportive care. This trial will evaluate whether a structured plant-based dietary strategy reduces chemotherapy-induced gastrointestinal toxicity (CIGT) and improves related biological and patient-centered outcomes. Methods This multicentre, stratified, three-arm, parallel-group, assessor-blinded, superiority randomised controlled trial will enrol 114 adults (18–65 years) with pathologically confirmed CRC receiving (or scheduled to receive) FOLFOX chemotherapy at two hospitals in Chengdu, China. Participants will be randomised (1:1:1), stratified by study site and sex, to (1) a structured plant-based dietary strategy, (2) conventional dietary guidance, or (3) conventional dietary guidance plus an oncology complete nutritional formula, for 6 weeks. Assessments will be performed at baseline and at prespecified time points through week 6. Primary outcomes are (i) the participant-level incidence of any prespecified CTCAE gastrointestinal toxicity of grade ≥ 2 during follow-up, (ii) serum inflammatory biomarkers, and (iii) stool-based profiling. Secondary outcomes include dietary intake and diet quality, body composition by bioelectrical impedance analysis, routine clinical laboratory indices, fatigue, anxiety/depression, physical activity, and adverse events. Primary analyses will follow the intention-to-treat principle. Discussion This trial will provide evidence on the efficacy and safety of a plant-based dietary strategy to mitigate CIGT during FOLFOX chemotherapy. Integrated clinical, biomarker, and stool multi-omics measures may also support exploration of biological correlates of symptom burden and treatment tolerance. Trial registration Chinese Clinical Trial Registry (ChiCTR), ChiCTR2500095215; registered 03 January 2025. https://www.chictr.org.cn/showproj.html?proj=254099 .

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Peng et al. (2026) studied this question.

synapsesocial.com/papers/69a7cdaed48f933b5eeda332https://doi.org/10.1186/s13063-026-09573-y
Ask AI
Helpful
Bookmark
Share
View Full Paper